Lilly To Cease Development Of Alzheimer's Drug: A Blow To The Amyloid Hypothesis?
Executive Summary
Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent
You may also be interested in...
Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another
Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.
Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another
Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.
Roche Is Sudden Pioneer In Alzheimer's Research With New Trial In Early Patients
Using a biomarker and investigational diagnostic, Roche has initiated a Phase II clinical trial of an amyloid-beta peptide antibody, gantenerumab, in patients with only mild cognitive deficits.